• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment
 

The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment

Options
  • Details
BORIS DOI
10.7892/boris.107316
Date of Publication
2017
Publication Type
Article
Division/Institute

Institut für Patholog...

Contributor
Wasmer, Marie-Hélène Christin
Institut für Pathologie, Immunpathologie
Krebs, Philippeorcid-logo
Institut für Pathologie, Immunpathologie
Subject(s)

500 - Science::570 - ...

600 - Technology::610...

Series
Frontiers in immunology
ISSN or ISBN (if monograph)
1664-3224
Publisher
Frontiers Research Foundation
Language
English
Publisher DOI
10.3389/fimmu.2016.00682
PubMed ID
28119694
Uncontrolled Keywords

cancer

inflammation

tumor microenvironmen...

interleukin-33

therapy

Description
There is compelling evidence that inflammation contributes to tumorigenesis. Inflammatory mediators within the tumor microenvironment can either promote an antitumor immune response or support tumor pathogenesis. Therefore, it is critical to determine the relative contribution of tumor-associated inflammatory pathways to cancer development. Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines that is released upon tissue stress or damage to operate as an alarmin. IL-33 has been primarily implicated in the induction of type-2 immune responses. However, recent findings have shown a role of IL-33 in several cancers where it may exert multiple functions. In this review, we will present the current knowledge on the role of IL-33 in the microenvironment of different tumors. We will highlight which cells produce and which cells are activated by IL-33 in cancer. Furthermore, we will explain how IL-33 modulates the tumor-associated inflammatory microenvironment to restrain or promote tumorigenesis. Finally, we will discuss the issues to be addressed first before potentially targeting the IL-33 pathway for cancer therapy.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/155778
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
  View More
BORIS Portal
Bern Open Repository and Information System
Build: 960e9e [21.08. 13:49]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo